Division of Gastroenterology

Helga Witt-Sullivan

MD. FRCPC, C

Assistant Professor, Division of Gastroenterology, Department of Medicine

Administrative Assistant: Laurie Williams
905.527.0271 X44342
willilau@hhsc.ca

 

Biography

Dr Helga Witt-Sullivan graduated from McMaster University with a Bachelor of Physical Education (1980). She remained at McMaster University to complete her MD (1983). In Toronto, she pursued post graduate training in Internal Medicine, Gastroenterology, and Hepatology (2 years).

Dr Witt-Sullivan was appointed Assistant Professor at McMaster University in 1990, where her main focus has been on Hepatology. She is actively involved in providing hepatology training for the GI fellows. Her main research interests are in clinical based viral research studies.

Selected Publications

  1. The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada: the CASL Experience
    Zandieh, D, Krygier, V, Wong, J. Howard, L. Worobetz, G. Minuk, H. Witt-Sullivan, E. Yoshida
    Can J Gastroenterol 2008;22(4):388-392
  2. Consistency of Sustained Viral Response across Weight Categories: results from the Canadian POWeR (Peginterferon alfa-2b Prospective Optimal Weight based Dosing Response) Program
    SV. Feinman, C. Ghent, H. Witt-Sullivan, L. Scully, M. Poliquin, W. Ghesquire, R. Arlen, P. Marotta
    Abstract submission AASLD 2007
  3. Final Results of the Canadian POWeR (Peginterferon alfa-2b Prospective Optimal Weight based Dosing Response) Program. Sustained Viral Response to Weight-based Peginterferon alfa-2b + Ribavirin in a Large Mixed Community and Academic Observational Study
    P. Morotta, SV Feinman, C. Ghent. L.Scully, M. Varenbut, J. Daiter. H. Witt-Sullivan, J. Robert, B. Romanowski, J. Farley, N. Abadir, R. J. Bailey
    Abstract submission AASLD, 2007
  4. An Interim Analysis of the Canadian POWer Program (Peginterferon alfa – 2 b Prospective Optimal Weight-based Dosing Response): Consistent SVR Rates Across All weight Catagories
    P. Marotta, SV Feinman, C. Ghent, L Scully, M. Varenbut, J. Daiter, H. Witt-Sullivan, J. Robert, RJ. Bailey, B. Romanowski, J. Farley, N. Abadir
    AASLD 2006
  5. Treating chronic hepatitis C with Peginterferon alfa – 2 a (40KD) (Pegasys) plus ribovirin (Copegus) in Routine clinical practice : Factors predicting sustained virological response (SVR) using multiple logistic regression(MLR) analysis
    S.S. Lee, E. J. Heathcote, M. Sherman, SV. Feinman, V. Bain, E. Yoshida, H. Witt-Sullivan
    EAP Abstract to EASL 2006
  6. Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Interferon
    J. D. Collier, P. A. Adams, V. Feinman, C. Ghent, H. Witt-Sullivan, G. Minuk, M. Krajden, J. Heathcote
    The Canadian Journal of Gastroenterology, July/August 2000
  7. Total Plasma and Lipoprotein Lipid Profiles of Patients with Primary Biliary Cirrhosis
    A.Kuksis, H. Witt-Sullivan, K. Cauch0Dudek, G. Steiner, J. Heathcote
    Journal of Lipid Research, December 1998
  8. Treatment of Chronic Viral Hepatitis with Alpha-Interferon: A Consensus Conference Report
    P. Adams, F. Anderson, R. Bailey, V.G. Bain, V. Feinman, C. Ghent, J. Heathcote, S. Lee, G. Levy, T.I. Michalak, G. Minuk, K. Paradis, E. Roberts, L. J . Scully, E. Shaffer, A. H. Sherker, M. Sherman, M. Swain, J.P. Villeneauve, B. Willems, N. Williams, H. Witt-Sullivan
    Canadian Journal of Gastroenterology Vol 8 No 3 May/June 1994
    Canadian Journal of Infectious Diseases Vol 5 No.3, May/June 1994
  9. Viral Hepatitis A, B, C, D, & E
    J. Faught, J. Williams, H. Witt-Sullivan, S. Shannon
    Medical Practise Education: Practice-based small group learning project
    Information Sheet Vol.1 1995 – 96
  10. Chronic Hepatitis C – The Simplified Histological Activity Index as a Predicator of Response to Alpha-Interferon
    B. Carter, H. Witt-Sullivan, L. J. Elavathil
    Abstact: Presentation – The Royal College of Physicians & Surgeons of Canada and the Canadian Association of Pathologists
    Halifax, September 26-29 1996
  11. No Evidence for a More Atherogenic Serum Lipid Profile With Ursodeoxycholic Acid (UDCA) Therapy in Patients with Primary Biliary Cirrhosis (PBC)
    P. Michieletti, H. Witt-Sullivan, G. Steiner, K. Cauch, V. Walker, J. Heathcote
    American Association for the Study of Liver Diseases, November 1993
  12. Detailed Histologic Grading as a Predictor of Morbidity and Mortality in Primary Biliary Cirrhosis
    I.Wanless, J. Heathcote, K. Cauch and the Canadian PBC Trial Group
    American Association for the Study of Liver Disease, November 1993
  13. “Teaching tips paper”
    Christopher Allen, John Cairns, Moran Campbell, David Churchill, Deborah Cook, Robert Cornett, Greg Curnew, hertzel Gerstein, Brian Haynes, Ann Holbrook, Jack Hirsch, Roman Jaeschke, Mitchell Levine, Ralph Meyer, Alan Neville, Jim Nishikawa, Paul O’Byrne, Akbar Panju, Helen Ramsdale, Geral Ryan, David Sackett, Marion Salusinsky-Sternback, Susan Tainsh, William Walsh, H. Witt-Sullivan
    November 1993